Protocol Ledger

NCT03364153 · Phase II · COMPLETED

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Interventional Phase II clinical trial protocol NCT03364153 sponsored by Astellas Pharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-12 Enrollment: 121 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03364153
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)121 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03364153
Protocol FieldVerified Registry Value
NCT IdentifierNCT03364153
Consolidated Lead SponsorAstellas Pharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment121 participants (ACTUAL)
Registered Start Date2018-01-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI